Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus

International Journal of Infectious Diseases

Volumn 13, Issue 4, 2009, Pages 449-455

  Butt, Adeel A ^a,b   Tsevat, Joel ^c   Leonard, Anthony C ^c   Shaikh, Obaid S ^a   McMahon, Deborah ^a   Khan, Uzma A ^d   Dorey Stein, Zachariah ^e   Re III, Vincent Lo ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Center for Health Equity Research and Promotion   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d ALBANY MEDICAL CENTER   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Co infection; Hepatitis C virus; HIV; Racial disparity; Treatment rates

Indexed keywords

ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; ALCOHOL ABUSE; ARTICLE; BIVARIATE ANALYSIS; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION RISK; INFORMATION PROCESSING; INTERVIEW; LIVER BIOPSY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MULTIVARIATE ANALYSIS; NEGRO; PRESCRIPTION; PROSPECTIVE STUDY; RACE DIFFERENCE; SEX RATIO; STATISTICAL SIGNIFICANCE; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; ALCOHOLISM; ANTIVIRAL AGENTS; CONTINENTAL POPULATION GROUPS; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; ODDS RATIO; OHIO; PATIENT SELECTION; PENNSYLVANIA;

EID: 67349228427     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.06.041     Document Type: Article

References (20)

1. Zeuzem S., Feinman S.V., Rasenack J., Heathcote J., Lai M.Y., Gane E., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343 (2000) 1666-1672
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med 347 13 (2002 Sep 26) 975-982
3. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 5 (2004) 346-355
4. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 5 (2004) 451-459
5. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 5 (2004) 438-450
6. Butt A.A., Wagener M., Shakil A.O., and Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 12 (2005) 81-85
7. Butt A.A., Justice A.C., Skanderson M., Rigsby M., Good C.B., and Kwoh C.K. Rate and predictors of treatment prescription for hepatitis C. Gut 56 (2007) 385-389
8. Butt A.A., Justice A.C., Skanderson M., Good C.B., and Kwoh C.K. Rates and predictors of HCV treatment in HCV-HIV coinfected persons. Aliment Pharmacol Ther 24 (2006) 585-591
9. Fultz S.L., Justice A.C., Butt A.A., Rabeneck L., Rodriguez-Barradas M.C., and Weissman S. Testing, referral, and treatment patterns for hepatitis C coinfection in a cohort of veterans with HIV infection. Clin Infect Dis 36 (2003) 1039-1046
10. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 (2004) 2839-2848
11. Goulet J.L., Fultz S.L., McGinnis K.A., and Justice A.C. Relative prevalence of comorbidities and treatment contraindications in HIV mono-infected and HIV/HCV co-infected veterans. AIDS 19 Suppl 3 (2005) S99-105
12. Butt A.A., Khan U.A., McGinnis K.A., Skanderson M., and Kwoh C.K. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 14 (2007) 890-896
13. Butt A.A. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read 13 (2003) 344-348
14. Bach P.B., Cramer L.D., Warren J.L., and Begg C.B. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341 (1999) 1198-1205
15. Petersen L.A., Normand S.L., Leape L.L., and McNeil B.J. Comparison of use of medications after acute myocardial infarction in the veterans health administration and Medicare. Circulation 104 (2001) 2898-2904
16. Peterson E.D., Shaw L.K., DeLong E.R., Pryor D.B., Califf R.M., and Mark D.B. Racial variation in the use of coronary-revascularization procedures-are the differences real? do they matter?. N Engl J Med 336 (1997) 480-486
17. Kinzie J.L., Naylor P.H., Nathani M.G., Peleman R.R., Ehrinpreis M.N., Lybik M., et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than caucasians. J Viral Hepat 8 (2001) 264-269
18. Daniel S. Chronic hepatitis C treatment patterns in African American patients: an update. Am J Gastroenterol 100 (2005) 716-722
19. McGinnis K.A., Fine M.J., Sharma R.K., Skanderson M., Wagner J.H., Rodriguez-Barradas M.C., et al. Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health 93 10 (2003) 1728-1733
20. Macias J., Giron-Gonzalez J.A., Gonzalez-Serrano M., Merino D., Cano P., Mira J.A., et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 55 3 (2006) 409-414